Search Results - "Hahne, W. F."

Integrated acidity and rabeprazole pharmacology by Gardner, J. D., Perdomo, C., Sloan, S., Hahne, W. F., Barth, J. A., Rodriguez‐Stanley, S., Robinson, M.

“…Background: Integrated gastric and oesophageal acidity can be calculated from measurements of gastric and oesophageal pH and used to quantify gastric and…”
Get full text

Intravenous Dolasetron for the Prevention of Postoperative Nausea and Vomiting After Outpatient Laparoscopic Gynecologic Surgery by Graczyk, Sarena G., McKenzie, Ray, Kallar, Surindar, Hickok, Charles B., Melson, Timothy, Morrill, Bruce, Hahne, William F., Brown, Robert A.

“…The newer 5-hydroxytryptamine type 3 (5-HT3) antagonists are sometimes considered for routine prophylaxis of postoperative nausea and vomiting (PONV) in…”
Get full text

Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin by Kris, M G, Grunberg, S M, Gralla, R J, Baltzer, L, Zaretsky, S A, Lifsey, D, Tyson, L B, Schmidt, L, Hahne, W F

“…This dose-ranging trial of intravenous dolasetron mesylate (MDL73,147EF) was performed to determine its adverse and antiemetic effects in patients receiving…”
Get more information

Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting by DIEMUNSCH, P, LEESER, J, HAHNE, W. F, FEISS, P, D'HOLLANDER, A, BRADBURN, B. G, PAXTON, D, WHITMORE, J, PANOUILLOT, P, NAVE, S, BROWN, R. A

“…To compare the efficacy, safety, and tolerability of dolasetron mesilate with placebo for the treatment of postoperative nausea and vomiting (PONV). In a…”
Get full text

Proglumide and Benzotript: Members of a Different Class of Cholecystokinin Receptor Antagonists by Hahne, W. F., Jensen, R. T., Lemp, G. F., Gardner, J. D.

“…In dispersed acini from guinea pig pancreas, proglumide (DL-4-benzamido-N,N-dipropylglutaramic acid) and benzotript (N-p-chlorobenzoyl-L-tryptophan) caused a…”
Get full text

A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers by Hunt, T L, Cramer, M, Shah, A, Stewart, W, Benedict, C R, Hahne, W F

“…The safety and tolerability of dolasetron mesylate, a potent and selective 5-HT3 receptor antagonist, were evaluated after single intravenous doses in healthy…”
Get more information

A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis by HARMAN, G. S, OMURA, G. A, RYAN, K, HAINSWORTH, J. D, CRAMER, M. R, HAHNE, W. F

“…Intravenous dolasetron has been shown to be an effective antiemetic agent in patients receiving high-dose cisplatin-containing chemotherapy. Previous studies…”
Get full text

Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide by HESKETH, P. J, GANDARA, D. R, HESKETH, A. M, FACADA, A, PEREZ, E. A, WEBBER, L. M, MARTIN, L. A, CRAMER, M. B, HAHNE, W. F

“…Selective 5-HT3 antagonists have proven to be safe and effective for the prevention of chemotherapy-induced nausea and vomiting. Dolasetron is a new highly…”
Get full text

Single-dose, placebo-controlled, phase I study of oral dolasetron by Dixon, R M, Cramer, M, Shah, A K, Whitmore, J, Benedict, C R, Hahne, W F

“…To evaluate the safety, tolerability, and pharmacokinetics of single, escalating doses of oral dolasetron mesylate, a new 5-HT3 receptor antagonist…”
Get more information

Pharmacokinetics of Dolasetron after Oral and Intravenous Administration of Dolasetron Mesylate in Healthy Volunteers and Patients with Hepatic Dysfunction by Stubbs, Katherine, Martin, Lorene A., Dimmitt, Dan C., Pready, Nick, Hahne, William F.

“…In previous studies, dolasetron was shown to have both renal and hepatic elimination mechanisms. This study was conducted to determine the impact of varying…”
Get full text

Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2 by Dimmitt, Dan C., Choo, Youn Sung, Martin, Lorene A., Arumugham, Thangam, Hahne, William F., Weir, Scott J.

“…The single‐ and multiple‐dose pharmacokinetics and dose‐proportionality of oral dolasetron and its active metabolites over the therapeutic dose range was…”
Get full text

Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting: Pooled analysis of 14 clinical trials by WHITMORE, J. B, KRIS, M. G, HESKETH, P. J, GROTE, T. H, DUBOIS, D. M, CRAMER, M. B, HAHNE, W. F

“…Dolasetron mesilate is a selective 5-HT3 receptor antagonist that prevents chemotherapy-induced and postoperative nausea and vomiting. For the majority of…”
Get full text

A Double-Blind, Randomized Study of Two Different Dosage Regimens of Intravenous Dolasetron in Patients Receiving High-Dose Cisplatin Chemotherapy by Kasimis, Basil S., Tapazoglou, Efstathios, Schulman, Phillip, Stewart, William H., Hahne, William F., Cramer, Michael B.

“…This study compared the antiemetic efficacy and safety of two different intravenous (IV) dolasetron dosing regimens in patients receiving their first course of…”
Get full text

Multiple-dose, placebo-controlled, phase I study of oral dolasetron by Hunt, T L, Cramer, M, Christy-Bittel, J, Shah, A K, Meyerson, L J, Benedict, C R, Hahne, W F

“…To evaluate the safety, tolerability, and pharmacokinetics of increasing dose levels of oral dolasetron mesylate, a new 5-HT3 antagonist. Double-blind,…”
Get more information

Randomized comparison of the antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL 72,222) with a high-dose metoclopramide regimen by Homesley, H D, Hahne, W F, McLees, B, Heck, K, Barrett, R J, Lentz, S S, Woodlief, L, Lovelace, J V

“…This pilot randomized study compared MDL 72,222, a highly selective 5-HT3 receptor antagonist, with a high-dose metoclopramide regimen (HDM) for…”
Get more information

Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome by VINAYEK, R, HAHNE, W. F, EULER, A. R, NORTON, J. A, JENSEN, R. T

“…Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome is increasingly required; however, existing methods of…”
Get full text

Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1 by Dimmitt, Dan C., Choo, Youn Sung, Martin, Lorene A., Arumugham, Thangam, Hahne, William F., Weir, Scott J.

“…In this first part of a two‐part investigation, the intravenous dose proportionality of dolasetron mesylate, a 5‐HT3 receptor antagonist, and the absolute…”
Get full text

Treatment of Postoperative Nausea and Vomiting with Single Intravenous Doses of Dolasetron Mesylate: A Multicenter Trial by Kovac, Anthony L, Scuderi, Phillip E, Boerner, Thomas F, Chelly, Jacques E, Goldberg, Michael E, Hantler, Charles B, Hahne, William F, Brown, Robert A

“…This study was conducted to determine the efficacy and safety of four intravenous (IV) doses of dolasetron, an investigational 5-HT3 receptor antagonist, for…”
Get full text

Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery by Diemunsch, Pierre, D'Hollander, Alain, Paxton, Lionel, Schoeffler, Pierre, Wessel, Pierrette, Navé, Stephane, Brown, Robert A., Hahne, William F.

“…Study Objective: To evaluate a range of doses of intravenous (IV) dolasetron mesilate, in preventing postoperative nausea and vomiting (PONV). Design:…”
Get full text

Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy by Yeilding, A, Bertoli, L, Eisenberg, P, Plezia, P, Modiano, M R, Alberts, D S, Khojasteh, A, Cramer, M B, Hahne, W F

“…This randomized, double-blind, parallel-group, multicenter study compared the antiemetic effectiveness, safety, and tolerability of two different intravenous…”
Get full text